AbbVie Inc. (ABBV), Monday reported positive topline results from its Phase 3b/4 SELECT-SWITCH study comparing upadacitinib 15 mg once daily with adalimumab 40 mg every other week in adults with moderate to severe rheumatoid arthritis who had an inadequate response to another TNF inhibitor.
At week 12, the study's primary and most secondary endpoints were met, and no new safety risks were identified. By week 12, 43.3 percent of RINVOQ patients had low disease activity compared to 22.4 percent of HUMIRA patients, and 28.4 percent had remission compared to 14.5 percent, both of which were statistically significant.
ABBV is currently trading at $230.82, up $1.24 or 0.54 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.